Novel angiogenesis inhibitors in nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 27, Issue 2, 2015, Pages 79-86

  Reinmuth, Niels ^a,b   Heigener, David ^a,b   Reck, Martin ^a,b  

^a LungenClinic Großhansdorf ^*  (Germany)

^b German Center for Lung Research (DZL)   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Nivolumab; Ramucirumab; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DOCETAXEL; NINTEDANIB; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; TAXOID; VASCULOTROPIN A;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; HUMANS; INDOLES; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922665326     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000166     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
3. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008; 14:6371-6375.
4. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 2001; 91:1500-1509.
5. Reinmuth N, Piegelbrock E, Raedel M, et al. Prognostic significance of vessel architecture and vascular stability in nonsmall cell lung cancer. Lung Cancer 2007; 55:53-60.
6. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049.
7. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20:3906-3927.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
10. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
12. Zhou C, Chen G, Liu X, et al. A randomized, double-blind, placebo controlled, multicentre, phase III study of first-line carboplatin/paclitaxel (CP) plus bevacizumab (BV) or placebo (PL) in Chinese patients with advanced or recurrent nonsquamous nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2013; 8:; MO06.13.
13. Thomas M, Reuss A, Fischer JR, et al. Innovations: randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) nonsmall cell lung cancer (NSCLC). J Clin Oncol 2011; 29:; abstr 7504.
14. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-4750.
15. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced nonsmall-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377:1846-1854.
16. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced nonsmall cell lung cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e22681.
17. Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2013; 24:20-30.
18. Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevaci-zumab-based therapy in advanced nonsquamous nonsmall-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733-740.
19. Lynch TJ Jr, Spigel DR, Brahmer J, et al. Safety and effectiveness of bevaci-zumab-containing treatment for nonsmall-cell lung cancer: final results of the ARIES observational cohort study. J Thorac Oncol 2014; 9:1332-1339.
20. Reck M, Barlesi F, Crino L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012; 23:1111-1120.
21. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473-2483.
22. Mok T, Gorbunova V, Juhasz E, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous nonsmall-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol 2014; 9:848-855.
23. Reck M, Popat S, Reinmuth N, et al. Metastatic nonsmall-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 3):iii27-iii39.
24. Ellis PM, Al-Saleh K. Multitargeted antiangiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol 2012; 84:47-58.
25. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
26. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009; 52:4466-4480.
27. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9:2825-2833.
28. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2009; 16:311-319.
29. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2012; 23:2094-2102.
30. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated nonsmall cell lung cancer patients. Clin Cancer Res 2010; 16:2881-2889.
31. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced nonsmall-cell lung cancer. Ann Oncol 2012; 22:1374-1381.
32. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated nonsmall-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15:143-155.
33. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31:abstr. 8034.
34. Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97:393-399.
35. Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013; 13:1187-1196.
36. Sweeney P, Karashima T, Kim SJ, et al. Antivascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8:2714-2724.
37. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-787.
38. Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2014; 9:1532-1539.